Injectable abaloparatide is being evaluated in the U.S. and Europe to treat postmenopausal women with osteoporosis…

Subcategories:AnalgesicsBiologics/DMARDs
Injectable abaloparatide is being evaluated in the U.S. and Europe to treat postmenopausal women with osteoporosis…
Natalie Grover |
(Reuters)—The U.S. Food and Drug Administration needs Corbus Pharmaceuticals to show positive data from only one late-stage study on its experimental treatment for scleroderma to support a marketing application, the company said. Corbus said on Wednesday it expects to start the study on 270 patients in the fourth quarter and that it was in talks…
In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…
Reuters Staff |
(Reuters)—U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation’s top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country’s deadly opioid crisis. The Missouri senator’s investigation comes amid an epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according…
Introduction: Major advances in the past two decades have enhanced our understanding of the complex interactions between the immune system and cancer cells and their environment. Genetic and epigenetic alterations in tumor cells result in the expression of diverse antigens that can elicit an immune response, primarily mediated by T cells. Immune responses are regulated…
Ronnie Cohen |
(Reuters Health)—In states that legalized medical marijuana, U.S. hospitals failed to see a predicted influx of pot smokers, but in an unexpected twist, they treated far fewer opioid users, a new study shows. Hospitalization rates for opioid painkiller dependence and abuse dropped on average 23% in states after marijuana was permitted for medicinal purposes, the…
When compared with TNFIs, ustekinumab demonstrated a longer drug survival rate in patients with severe plaque psoriasis…
Reuters Staff |
NEW YORK (Reuters Health)—After starting biologic therapy for rheumatoid arthritis (RA), patients with higher disease activity at baseline achieved greater improvements in measures of disease activity than those with lower levels of disease, but they were less likely to achieve remission or even low disease activity, according to a new real world analysis of registry data….
Recent research analyzed factors influencing the selection of the first-line biologic medications and the real-life factors that lead to switching from those medications to other biologics in treating rheumatoid arthritis (RA). The study compared the use of abatacept and tocilizumab with a tumor necrosis factor alpha inhibitor (TNFi).1,2 Participants were enrolled in the Lombardy Rheumatology…
Scott Baltic |
NEW YORK (Reuters Health)—A father’s exposure to methotrexate 90 days or less before conception “should not be of major concern,” researchers say. Prepregnancy paternal methotrexate exposure appears to confer no increased risk of major or minor congenital malformation, stillbirth or preterm birth in his offspring, their study found. Methotrexate is a first-line therapy for rheumatoid…